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Abstract
White matter abnormalities on magnetic resonance imaging (MRI) are associated with
dementia and include white matter hyperintensities (WMH; also termed leukoaraiosis) and
visible perivascular spaces (PVS). We review the potential role of impaired drainage of
interstitial fluid in the pathogenesis of WMH and PVS.Whereas the volume of extracellular
space in the grey matter is tightly controlled, fluid accumulates and expands the
extracellular spaces of the white matter in acute hydrocephalus, vasogenic edema and
WMH. Although there are no conventional lymphatic vessels in the brain, there is very
effective lymphatic drainage for fluid and solutes along restricted pathways in the basement
membranes of cerebral capillaries and arteries in young individuals. Lymphatic drainage of
the brain is impaired with age and in association with apolipoprotein E ε4, risk factors for
Alzheimer’s disease and cerebral amyloid angiopathy (CAA). Deposition of proteins in the
lymphatic drainage pathways in the walls of cerebral arteries with age is recognized as
protein elimination failure angiopathy (PEFA), as in CAA and cerebral autosomal domi-
nant arteriopathy and leukoencephalopathy (CADASIL). Facilitating perivascular lym-
phatic drainage from the aging brain may play a significant role in the prevention of CAA,
WMH and Alzheimer’s disease and may enhance the efficacy of immunotherapy for
Alzheimer’s disease.
INTRODUCTION
Leukoaraiosis, seen as cerebral white matter hyperintensities
(WMH) on magnetic resonance imaging (MRI) or low attenuation
on computed tomographic scanning (CT), is frequent in patients
with dementia. However, the causes are unclear and appear to be
multiple. It has long been assumed that WMH are due to arterio-
sclerotic small vessel disease and infarction but another strong
candidate is emerging as a result of MRI, clinical and pathological
studies. This strong candidate is the failure of elimination of inter-
stitial fluid (ISF) from white matter, especially associated with
cerebral amyloid angiopathy (CAA) (92), but also related to other
disorders of small cerebral blood vessels such as cerebral
autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy (CADASIL) (16). Pathological studies and
detection of dilated perivascular spaces (PVS) by MRI in the white
matter in association with evidence of CAA-related intracerebral
hemorrhage support a relationship between CAA and impaired
drainage of ISF from the white matter. In the wider context, failure
of elimination of ISF from the aging brain indicates a failure in
disposal of soluble metabolites from the brain with a consequent
failure of homoeostasis of the neuronal environment with impor-
tant implications for the pathogenesis of dementia (16).
In this review, we first set the scene with a description of the
clinical and radiological aspects of leukoaraiosis and dilated PVS
in relation to intracerebral hemorrhage and lobar microbleeds
putatively because of CAA. This is followed by a brief account of
the production and elimination of cerebrospinal fluid (CSF) and
ISF from the brain and the interrelationships between CSF and ISF.
A more detailed account of how ISF and solutes drain from the
brain along basement membranes in the walls of cerebral capillar-
ies and arteries follows; such perivascular pathways represent the
lymphatic drainage pathways of the brain. Major pathologies of
ISF drainage include its failure with age and the deposition of
amyloid-β (Aβ) and other proteins, such as CADASIL-derived
material, within basement membranes of the perivascular drainage
pathways. Evidence will be presented that perivascular drainage of
ISF and solutes is impaired with age, CAA and Alzheimer’s
disease (AD) and in individuals possessing the ε4 allele of
apolipoprotein E (APOE4).
The failure of trials of anti-Aβ immunotherapy to show signifi-
cant clinical improvement in AD has been extensively discussed.
Despite evidence that insoluble plaques of Aβ are removed from
the brain in immunized patients (79) and in experimental animals
(97), there is an increase in severity of CAA and WMH in asso-
ciation with immunotherapy (79).We therefore review the possible
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role of immune complexes in the impairment of perivascular elimi-
nation of Aβ from the brain. Finally, we examine the generic
concept of protein elimination failure angiopathy (PEFA) that
includes Aβ and other amyloid angiopathies together with prion
angiopathies and CADASIL. In this way, we seek to emphasize the
wide range of pathologies that are associated with failure of
perivascular drainage of ISF and solutes from the brain, particu-
larly in the aging population.
CLINICAL SIGNIFICANCE OF WMH AND
DILATED PVS
The term leukoaraiosis [from the Greek λευκος (leukos): white;
and αραιο´ς (araios): rarefied] was coined by Hachinski et al in
1986 (48) to describe changes in the hemispheric cerebral white
matter seen on neuroimaging: initially as areas of low attenuation
on CT and subsequently as hyperintensities on T2-weighted or
Fluid Attenuated Inversion Recovery (FLAIR) MRI. The term was
developed to avoid ascribing a particular pathological cause to
these increasingly detected imaging findings, which may reflect a
range of pathological processes in different populations (eg, in
younger patients may be due to leukodystrophy or inflammatory
demyelination). Leukoaraiosis is common in patients with cogni-
tive impairment including dementia as well as those with sympto-
matic cerebrovascular disease (29). In this review, we focus on
leukoaraiosis in older individuals, in whom the changes have been
presumed to be due to cerebrovascular disease, principally affect-
ing small vessels. Here, we assess to what extent it is possible to
correlate fluid levels in white matter on MRI with dilated PVS
(Figure 1) and cerebral amyloid angiopathy.
Leukoaraiosis can be defined as white matter abnormality (low
density on CT, hyperintensity on T2-weighted or FLAIR MRI),
which may be patchy or confluent. These white matter appearances
on MRI have variously been termed white matter abnormalities,
white matter changes and WMH; a recent consensus group rec-
ommended the term “white matter hyperintensities of presumed
vascular origin” (111). The term leukoaraiosis nevertheless has the
advantage of being applicable to both CT and MRI. Here, we will
mainly focus on imaging changes seen on MRI, which will be
referred to as “white matter hyperintensities” (WMH).
White Matter Hyperintensities
WMH are commonly detected on MRI in various populations: in
the general population, the prevalence is between about 10% and
20% in the seventh decade of life and nearly 100% in the ninth
decade. WMH are more common and extensive in patients with
cardiovascular risk factors and symptomatic cerebrovascular
disease (69). WMH appear to be of clinical relevance because of
a strong relationship with vascular risk factors and cognitive
impairment in cross-sectional studies. WMH also contribute to
gait disturbance and falls (9). There is now also a strong evi-
dence that WMH are important for clinical prognosis: a system-
atic review of 958 published prospective studies found strong
evidence of an increased risk of stroke, cognitive decline (espe-
cially in the executive function and processing speed domains),
dementia and death (29). WMH were significantly associated
with an increased risk of stroke, both in the general population
and in high-risk populations with a history of stroke or vascular
disease, even after adjusting for the potential confounding effect
of vascular risk factors known to be associated with WMH (eg,
hypertension) (29). WMH were associated with an increased risk
of dementia in the general population but not in high-risk popu-
lations (29). The mechanisms underlying this association with
future cognitive risk may include direct damage to white matter
subcortical networks or aggravation of neurodegenerative pro-
cesses including AD. CT-defined leukoaraiosis has been associ-
ated with an increased risk of intracerebral bleeding in patients
with stroke treated with high intensity oral anticoagulation with
warfarin (43).
Finally, WMH may be a useful biomarker or “intermediate phe-
notype,” which could help to identify new genetic or environmen-
tal risk factors and potentially function as a surrogate end point in
clinical trials (111).
The pathological substrates of WMH include tissue rarefaction
associated with loss of myelin and axons, enlarged (dilated) PVS
(see: Pathology of Dilated PVS) and mild gliosis. These lesions are
located in deep hemispheric white matter, typically sparing the
subcortical U-fibers, and are often seen in association with vessels
affected by small vessel disease including arteriolosclerosis.
However, the pathological basis of WMH is heterogeneous (44) as
the basis of increased signal on T2-weighted and FLAIR MRI is
simply an increase in free tissue water content, which is not spe-
cific for any particular pathological process. Furthermore, the
degree of pathological heterogeneity appears to reduce as the
severity of MRI-defined lesions increases from small punctate
lesions to confluent WMH; the latter almost always have an
ischemic appearance with myelin loss, gliosis and small areas of
infarction (36).
Figure 1. T2-weighted axial image showing MRI-visible PVS in the
hemisphere white matter in a patient with CAA-related ICH.
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Pathophysiological mechanisms
underlying WMH
Despite their high prevalence and clear clinical relevance, the
pathophysiological mechanisms underlyingWMH remain unclear.
One hypothesis is that damage to small medullary perforating
vessels, which supply the white matter, causes chronic hypo-
perfusion, with associated disruption of the blood–brain barrier,
leading to both ischemic injury and chronic leakage of potentially
toxic plasma proteins into the white matter. However, which
comes first (ischemia or blood–brain barrier dysfunction) remains
controversial. Evidence supporting an ischemic mechanism of
WMH comes from the observation that some forms of hypoxic-
ischemic injury cause selective white matter injury (Figure 2). The
anatomy of the blood supply to cerebral white matter is also con-
sistent with a vulnerability of deep white matter regions to reduced
perfusion and ischemic injury. Moreover, cerebral blood flow is
reduced in areas of WMH in patients with small vessel disease
(83).
An alternative hypothesis is that WMH (known to be associated
with increased tissue water content) are due to alterations in CSF
flow. Normal pressure hydrocephalus is known to be associated
withWMH and experimental hydrocephalus causes changes in the
white matter that can be reversed by shunting (78). However, it is
also possible thatWMH causes ex vacuo dilatation of the ventricu-
lar system suggesting a possible reverse causation. It is suggested
that the increased accumulation of CSF in the ventricles raises
interstitial pressure in the periventricular parenchyma and causes
ischemia of the white matter (93). The potential contribution of
impaired ISF drainage toWMH outside the context of hydrocepha-
lus remains even more uncertain.
Dilated Perivascular Spaces
Dilated PVS seen on MRI (Figure 1) have recently emerged as a
new MRI marker of small vessel disease, as they are associated
with other MRI features of small vessel disease, including
lacunes and WMH (30). Dilated PVS have particular interest in
the study of ISF dynamics as they are closely linked to the estab-
lished clearance pathways for ISF and solutes along basement
membranes (15, 16) and are enlarged in patients with conditions
known to impair ISF drainage, including AD with associated
CAA (92). There is no detectable PVS around the arteries in the
cerebral cortex (127) whereas PVS may dilate in the white matter
and are thought to indicate failure of drainage of fluid and
solutes from the white matter (92) (see Pathology of dilated PVS
section).
Recent data in cohorts with intracerebral hemorrhage (ICH)
(another end result of small vessel disease, but in this case
causing fragility) indicate that the anatomical distribution of
MRI-visible dilated PVS is linked to the underlying small vessel
pathological process: in patients with lobar ICH attributed to
probable CAA, severe dilatation of PVS was noted in the cer-
ebral hemispheric white matter, while in other ICH cases (includ-
ing deep ICH attributed to arteriolosclerosis-related rupture of
deep basal ganglia perforating small vessels) severe dilatation of
PVS was found in the basal ganglia (Figure 2) (21). A similar
topographical association of hemispheric white matter PVS with
radiologically defined CAA was also noted in a memory clinic
cohort, supporting this hypothesis (72). The clinical relevance of
dilated PVS is less well established than that of WMH, with no
clear association shown with cognitive function (54) and no
available prospective data on the risk of future stroke or cognitive
impairment.
If dilated PVS in the hemispheric white matter are due to
impaired drainage of ISF then they should logically be associated
with markers of severe leptomeningeal and cortical arteriolar
amyloid deposition in CAA. Indeed, a recent study showed that
dilated PVS in hemisphericwhitematterwere strongly linked to one
such marker of severe superficial CAA, namely cortical superficial
siderosis (because of recurrent subarachnoid bleeding and
hemosiderin deposition from fragile, amyloid-laden superficial
vessels) (22). Another study used an amyloid-binding Positron
Emission Tomography (PET) ligand and showed that increased
amyloid binding was associated with the severity of WMH in
patients with CAA (but not AD), supporting the hypothesis that
vascular amyloid may aggravate or cause white matter injury in
CAA (47). However, ischemic injury to white matter associated
with CAA in small vessels perforating the cerebral cortex is also
possible (45) as an alternativemechanism to impaired ISF drainage.
An effect of amyloid on the pathogenesis ofWMH is also supported
by the finding that in AD, CAA, mild cognitive impairment and
whitematter changes correlatewith serum levels ofAβ1–40 peptide
(the main constituent of vascular amyloid deposits in CAA) (46).
PHYSIOLOGY AND PATHOLOGY OF
CSF AND ISF OF THE BRAIN
CSF and ISF are the major extracellular fluids associated with the
central nervous system (CNS). The total volume of CSF in humans
Figure 2. T2-weighted MRI axial image showing confluent WMH in
association with extensive deep (basal ganglia) MRI-visible perivascular
spaces and lacunar infarcts.
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is 140 mL with 30 mL in the ventricles and 110 mL within the
cerebral and spinal subarachnoid spaces; ISF has an estimated
total volume of 280 mL in the CNS (6).
Production and drainage of CSF
CSF is produced by the choroid plexuses with a probable contri-
bution from brain ISF (59). Following circulation through the
ventricular system, CSF enters the subarachnoid space and
passes directly into the blood through arachnoid granulations and
villi. An estimated 50% of CSF drains to cervical lymph nodes
(60) in smaller mammals along channels that pass from the
subarachnoid space through the cribriform plate of the ethmoid
bone to join nasal lymphatics (66). This pathway appears to be a
major pathway in small mammals and is also present in humans
(60, 66, 116).
Pathology of CSF
The major pathologies of the CSF are leptomeningitis, infiltra-
tion by neoplastic cells (carcinomatous/neoplastic meningitis),
and more important in the context of this paper, hydrocephalus
because of impaired drainage of CSF. In the acute stages of
hydrocephalus, interstitial edema of the periventricular white
matter may be observed (112) which suggests that there is
restricted capacity for ISF drainage from the white matter that
cannot cope with the excess of CSF in hydrocephalus. This may
be a further indication of the limited capacity of ISF drainage
from the white matter that is present in children with hydro-
cephalus and may be a factor in the pathogenesis of leukoaraiosis
in aging adults.
Lymphatic drainage of Interstitial Fluid
ISF is generated from the blood and from metabolic activity within
the brain tissue at an estimated rate of 0.1–0.3 μL/minute/g in the
rat (1). In the 1980s, Helen Cserr and her group showed that
radiolabeled human serum albumin, injected into ISF of the rat
brain, drained rapidly to cervical lymph nodes on the same side of
the neck (103). The drainage pathway was associated with the
walls of the arteries within the brain, leptomeningeal arteries and
the upper part of the internal carotid artery in the neck. Absence of
radiolabeled human serum albumin in the lower part of the internal
carotid suggested that most of the tracer had drained to the cervical
lymph nodes. The speed of perivascular drainage was comparable
with lymphatic drainage of other organs in the body and only 15%
of tracer leaked from the ISF drainage pathways in artery walls
into the CSF (103).
In more recent investigations of the ISF drainage pathways,
soluble lysine-fixable fluorescein-labeled 3 kDa dextran and Fluo-
rescein Isothiocyanate (FITC)-labeled ovalbumin (40 kDa) were
injected separately into the grey matter of the corpus striatum in
mouse brains. The distribution of the tracers was defined at 5
minutes, 30 minutes, 3 h and 24 h after injections. By 5 minutes,
dextran had spread diffusely in the brain parenchyma and was
within the basement membranes of capillary and artery walls
(Figure 3) (15). At 30 minutes, dextran had largely disappeared
from brain parenchyma and from the walls of capillaries and
arteries. At 3 h, dextran was present in a punctate form within
perivascular macrophages associated with capillaries and arteries
(15). Further analysis by confocal microscopy following intracer-
ebral injection of fluorescent dextrans and fluorescent soluble Aβ
revealed that tracers in the extracellular spaces of the brain paren-
chyma rapidly enter bulk flow pathways in basement membranes in
the walls of cerebral capillaries. From there, tracers drain into
basement membranes of smooth muscle cells within the tunica
media of cerebral arteries (Figure 3) (15, 114). These experiments
defined the 100–150 nm thick basementmembranes as the route for
lymphatic drainage of ISF and soluble metabolites from the brain.
The findings are highly relevant to the pathology of human
neurodegenerative disease as Aβ is deposited in this pathway in
CAA (Figure 4) (16) and relevant to neuroimmunology as antigens
may drain from the brain to regional lymph nodes in the neck as part
of the induction of neuroimmunological reactions (68, 118).
Figure 3. Perivascular drainage. ISF and
solutes, including Aβ, diffuse through the
extracellular spaces of the brain and then
drain out of the brain along basement
membranes (BM) in the walls of capillaries
and arteries. The drainage pathway is along
the BM colored green: that is capillary
endothelial BM and the BM of smooth
muscle cells (SMC) in the mid-zone of the
tunica media (TM) of the artery (BM2). In the
artery wall, BM on the outer aspect (BM1)
and on the endothelial aspect (BM3) is not
part of the drainage pathway. With reference
to Figure 8, immune complexes (*IC*) are
trapped within the BM2 pathway and
obstruct perivascular drainage. ENDO,
endothelium.
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Relationship between CSF and ISF
The brain is directly related to the CSF on its ventricular and
pial surfaces. CSF appears to play a major role as a buoyancy
fluid for the brain. Although there is a well-characterized
barrier between the blood and the brain, tracers injected into the
CSF diffuse into the surface of the brain and spinal cord as
shown by Goldman in 1913 (42). Injection studies by Rennels
et al in the 1980s (89) showed that horseradish peroxidase
injected into the cisterna magna diffused from the subarachnoid
space into the brain alongside arteries in the cerebral hemi-
spheres to reach capillary level. Fluid entry appeared to be
driven by vascular pulsations and was termed convective tracer
influx (89). Entry of tracers from the CSF into ISF was con-
firmed by the injection of fluorescent tracers that revealed an
entry pathway from the CSF into the brain along extravascular
compartments between cerebral arteries and brain parenchyma
(57, 58). Entry of low molecular weight tracers from the
paravascular pathway into the brain parenchyma is mediated by
aquaporin-4 associated with astrocytes in the brain (57). Because
of its association with astrocytes and the eventual drainage of
tracers to cervical lymph nodes, the name of the system has been
changed from the original terms of convective tracer influx to the
“glymphatic system.” The relationship between the glymphatic
system and the periarterial basement membrane drainage
pathway described in Figure 3 (15) for elimination of solutes
from the extracellular space of the brain is unclear. However, it
seems that the glymphatic system is a slow equilibration between
CSF and ISF. On the other hand, drainage of ISF and solutes
along basement membranes in the walls of the arteries is a much
more rapid response system that may play a signaling role
between solutes in the ISF and smooth muscle cells in the walls
of the arteries.
PATHOLOGY OF PERIVASCULAR
DRAINAGE OF ISF AND SOLUTES
FROM THE BRAIN
The pathology of perivascular drainage of ISF and solutes from the
brain relates to two major areas: first, neuroimmunology (68) and
second, the failure of ISF drainage in hydrocephalus and perhaps
more significantly in the aging brain, CAA and AD (116).
Antigens drain from the brain to regional lymph nodes in the
neck with ISF along basement membranes in the walls of capil-
laries and arteries (15, 103). However, this pathway is too narrow
to allow the migration of antigen-presenting cells from the brain
to cervical lymph nodes (15, 16). The absence of such effective
migration of antigen-presenting cells may be a major factor
in the relative immunological privilege of the brain (18, 118).
Evidence for a significant role for cervical lymph nodes in
neuroimmunological reactions in the brain comes from experi-
ments whereby the severity of experimental autoimmune
encephalomyelitis (EAE) is reduced by cervical lymphadenec-
tomy (87, 108). Antigen-presenting cells do appear to migrate
from the CSF to cervical lymph nodes via nasal lymphatics
and appear to play a role in the induction of immunological tol-
erance (68).
Deposition of amyloid in perivascular drainage
pathways in CAA
CAA is a major pathological manifestation of impaired ISF drain-
age (16). The presence of CAA in transgenic mice that produce
human Aβ solely in the brain is taken as firm evidence that CAA
is due to the failure of drainage of Aβ from the brain (53). A
number of amyloidogenic proteins are deposited in the basement
membranes in the walls of cerebral arteries, the most common of
Figure 4. Cerebral amyloid angiopathy. Aβ
(brown) is deposited in basement
membranes in the walls of capillaries (A) and
arteries (B,C). Although the basement
membranes of smooth muscle cells (SM) in
the tunica media contain Aβ (see figures B
and C), the endothelial basement membrane
(Endo BM) is almost devoid of Aβ.
Immunocytochemistry for Aβ (brown or red)
and smooth muscle actin (green). Collagen
IV in basement membrane in (C) is blue.
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which is Aβ associated with AD (90). Other amyloids such as
cystatin, transthyretin and certain forms of prion protein and the
Notch-3 associated protein in CADASIL are also deposited in
cerebral vessel walls (16). These disorders have been grouped
under the collective term PEFA (16). One of the major pathologi-
cal effects of impairment of perivascular drainage of ISF and
solutes from the brain with age and CAA appears to be loss of
homoeostasis of the extracellular environment in the brain, so that
metabolites such as soluble Aβ and probably other metabolites
accumulate within brain tissue in AD (71, 76). Such a change in
the extracellular environment of neurons may result in oxidative
stress and ultimately in dementia.
The distribution of Aβ in the walls of cerebral capillaries and
arteries in the early stages of CAAmirrors exactly the pathways by
which ISF and solutes drain from the brain (16) (Figures 3 and 4).
Electron microscope studies indicate that Aβ is initially deposited
as fibrils in the central portion (lamina densa) of basement mem-
branes surrounding smooth muscle cells (120), although at the
time the authors suggested that the Aβ was derived from vascular
myocytes rather than from the brain. One of the major questions
about CAA is exactly why amyloid is deposited in basement
membranes in the walls of cerebral capillaries and arteries.
What interferes with the perivascular drainage of soluble Aβ that
causes it to precipitate as fibrillar amyloid in vascular basement
membranes?
Age and possession of the ε4 allele of APOE4 are major risk
factors for CAA and for AD and the next section of this review
shows how both these factors impede the drainage of ISF and
solutes along perivascular pathways.
Impairment of perivascular drainage of ISF and
solutes with age and in the presence of apoE4
Age and possession of APOE4 allele are the strongest risk factors
for the development of sporadic AD and CAA. Experiments
described here show that age, CAA and possession of APOE4 are
associated with impaired perivascular drainage of ISF and solutes,
including Aβ.
Perivascular drainage of Aβ was assessed by confocal micros-
copy following intracerebral injection of 0.5 μL fluorescent
dextran or soluble humanAβ40 over a period of 2 minutes into the
hippocampus in three groups of animals. First: To test the effects
of age on perivascular drainage, intracerebral injections of fluo-
rescent dextran were performed on young and aged wild-type
C57B1/6 mice, at 3, 7 and 22 months of age (49). Second: To
assess the effect of CAA on perivascular drainage, fluorescent
dextran was injected into the brains of Tg2576 transgenic mice
with CAA (49). Third: To test the effects of APOE4 on
perivascular drainage, intracerebral injection of soluble Aβ40 was
performed in targeted replacement (TRE) mice carrying the
human APOE ε3 or APOE ε4 allele (50).
The results of these studies showed that perivascular drainage
was significantly (P < 0.001–P < 0.05) impaired in capillaries and
arteries:
(i) in 22-month-old wild-type mice compared with 3- and
7-month-old animals [furthermore, age-related changes in the
levels of laminin, fibronectin and perlecan in vascular basement
membranes were observed in these animals (49)] and
(ii) in 7- and 22-month-old Tg2576 mice with CAA (49).
(iii) In addition, Aβ40 aggregated in periarterial drainage path-
ways in APOE ε4 mice, but not in APOE ε3 or wild-type mice
(Figure 5) (50). The number of Aβ deposits was significantly
higher in the hippocampi of APOE ε4 mice than in the APOE ε3
mice, at both 3 and 16 months of age, indicating that clearance of
Aβ from the brain was disrupted in APOE ε4 mice (50).
In summary, the results of these studies suggest that age, pos-
session of APOE ε4 and the presence of CAA all result in impaired
perivascular drainage of solutes, includingAβ, from the brain. This
raises the question as to exactly why these factors interfere with
perivascular drainage and whether these data apply directly to
humans.
Age changes in arteries and distribution of Aβ
in plaques and CAA
Aged changes in human cerebral arteries are well recognized, with
generalized intimal thickening and fibrosis of the tunica media in
arteriosclerosis (115). Theoretical and experimental studies
suggest that the motive force for perivascular drainage of ISF
and solutes is derived from vascular pulsations (2, 98). As
arteries age, they become stiffer (115) which would imply that the
amplitude of vascular pulsations is reduced. Such a reduction in
pulsations may reduce the motive force for perivascular drainage
and the consequent slowing of drainage may allow Aβ fibril
formation to occur within the basement membranes of the
perivascular pathways, particularly as the nature of the basement
membrane proteins change with age. Deposition of Aβ in base-
ment membranes in CAA appears to further impede perivascular
drainage (49).
ApoE colocalizes with Aβ within plaques in the brain paren-
chyma and in CAA (106). It is thought that ApoE is a transport
molecule for Aβ. Our experiments suggest that Aβ is not
transported along perivascular pathways as efficiently in the pres-
ence of apoE4 compared to apoE3 (50). The exact reasons for
this are not clear but may be related to a difference in association
between the isoforms of APOE and basement membrane proteins
or an effect of APOE genotype on composition of basement
membranes.
There are regional differences in the deposition ofAβ as plaques
and CAA in the brains of aging and AD patients (105). CAA is
observed predominantly in the parietal and occipital cerebral
cortex, less so in the basal ganglia and thalamus and rarely in
vessels of the brain stem. Experiments in which Aβ was injected
into different areas of aged mouse brains showed that perivascular
drainage from the hippocampus became less efficient with age,
whereas there was little change in perivascular drainage from the
thalamus with age (51). These results suggest that there is a dif-
ferential effect of age on perivascular drainage in different
regions of the brain and this may have some bearing on the distri-
bution of CAA and the deposition of amyloid as plaques in the
brain in AD.
Biochemical and morphological changes in
blood vessels of the grey matter that
contribute to impaired drainage of ISF
Although the mechanisms underlying disrupted perivascular
drainage in the aged and ApoE4 brain have not been fully
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elucidated, multiple lines of evidence support a role for morpho-
logical and biochemical changes in blood vessel walls in the patho-
genesis of CAA. In vitro, aggregation of Aβ is inhibited and
preformed fibrils are destabilized in the presence of the basement
membrane proteins laminin, nidogens and collagen IV. By con-
trast, incubation of Aβ with heparan sulphate proteoglycans, such
as agrin and perlecan, accelerate its aggregation. In mice, brain
regions that are vulnerable to CAA show age-related decreases in
laminin, collagen IV and nidogen 2 and increased levels of
fibronectin and perlecan (51). Decreased amounts of collagen IV
have been reported in small diameter vessels (<50 μm) in the grey
matter in AD, compared with age-matched controls (23). Con-
versely, the levels of heparan sulphate proteoglycans were
increased in AD brains (99). These data suggest that age-related
changes in the expression of individual basement membrane pro-
teins may contribute to a pro-amyloidogenic environment within
the vessel wall.
Less is known about the effect of ApoE genotype on the bio-
chemistry of cerebral blood vessels, but a significant reduction in
the surface area of agrin immunoreactivity has been reported in
the brains of AD patients homozygous for the APOE ε4 allele
(94). Changes in the levels of collagen IV between 3 and 16
months are greater in TRE4 than in TRE3 mice (50), suggesting
that APOE genotype may also influence the degree to which
expression of basement membrane proteins changes over the
lifespan.
Age-related changes in the morphology of grey matter vessels
include splitting, duplication and thickening of the basement mem-
brane, particularly in areas of the brain that are susceptible to AD
pathology and CAA (51, 126). The contribution of basement mem-
brane abnormalities to the pathogenesis of CAA is suggested by
the observation that an increase in thickness of basement mem-
branes precedes endogenous CAA development in transforming
growth factor-β (TGF-β) transgenic mice (121). Increased rigidity
in the artery walls, elongation and tortuosity, as well as a reduction
in smooth muscle cells are also observed in the aging brain (63).
This reduction in vascular elasticity and contractile force may
diminish the amplitude of the arterial pulse and slow the driving
force for perivascular clearance of ISF and Aβ, leading to its
accumulation as CAA.
Pathology of dilated PVS
Dilatation of PVS occurs in the white matter of the cerebral hemi-
spheres (Figure 1), in the midbrain and in the grey matter of the
basal ganglia. In some cases, large giant lacunae form in these
areas of the brain (95); in most cases, however, the dilatation is
more moderate.
PVS, which is the potential space between the outer aspect
of an artery wall and the brain parenchyma, can be expanded
experimentally by the intracerebral injection of Indian ink particles
(128) or fluorescent polystyrene beads (fluorospheres) (15).
However, the PVS does not appear to function as a fluid drainage
pathway in the same way as the basement membrane pathways
within the artery walls themselves. Injection of pharmacolo-
gical preparations into the brain to expand PVS (intrastriatal
convection-enhanced delivery) has been developed to create a
reservoir for slow release of drugs for the treatment of neurological
disorders (5).
There is evidence that dilatation of PVS in the white
matter is associated with CAA (92). Figure 6 shows how
Figure 5. Leptomeningeal arteries from
wild-type and APOE ε4 mice following
intracerebral injection of fluorescent Aβ
(green). Within 5 minutes of the injection,
Aβ was observed along basement
membranes, colocalizing (pink) with collagen
IV (blue) in young, 3-month-old wild-type
mice in (A). Aggregation of Aβ is seen as
early as 3 months in the APOE4 mice (arrow
in B). Aβ continues to drain along basement
membranes of aged wild-type mice (C), but
appears as large deposits in 16 months in
the APOE ε4 mice (D, arrows). Scale
bars = 10 μm in A; 25 μm in B, C and D.
Reproduced from reference (50).
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branches of the leptomeningeal arteries on the surface of the
brain pass through the cerebral cortex, often without bran-
ching, to supply the underlying white matter (33). Perivascular
drainage of fluid and solutes from the white matter seems to be
impaired by CAA in the parent leptomeningeal or cortical arter-
ies with consequent dilatation of PVS in the white matter (92)
(Figure 6). Dilatation of PVS in the cortical grey matter is rarely
seen.
The other major site for dilated PVS is the grey matter of the
basal ganglia. This is evident in several diseases involving
small cerebral arteries. The structure of arteries in the basal
ganglia differs from arteries in the cerebral cortex (88, 127). As
arteries enter the surface of the cerebral cortex, the pia mater is
reflected from the surface of the brain on to the vessels in the
subarachnoid space, thus separating the subarachnoid space from
the cerebral cortex (55, 113, 127). There is no PVS around cor-
tical arteries in the normal brain as layers of smooth muscle,
basement membrane and one layer of leptomeninges are all com-
pressed together (127). In the basal ganglia, however, there are
two layers of leptomeninges surrounding the artery with a PVS
between the layers (88). This anatomical arrangement may
explain why there is no expansion of PVS in the cortex, whereas
perivascular lacunae are frequently seen in the basal ganglia
(95, 113).
WMH AND CAA IN Aβ
IMMUNOTHERAPY TRIALS FOR AD
Aβ immunotherapy impairs the elimination of
solutes from the brain
Trials of immunotherapy for AD in humans were introduced after
successful studies in human amyloid precursor protein (hAPP)
transgenic mice showed that insoluble Aβ plaques were removed
from the brain following immunization with Aβ42 (97). However,
despite the clearance of plaques in patients with AD (39, 73, 79),
active immunization seemed to increase, rather than decrease, the
amount of arterial CAA both in transgenic animals and in humans
(79, 119). It appears that Aβ can be solubilized from the plaques
but becomes trapped in the perivascular drainage pathway (85,
117), manifesting as an increase in the severity of CAA. The
dynamics of the events resulting in increased CAA following
immunotherapy are not clear but it could reflect either increasing
flow of Aβ out of the brain in the perivascular drainage pathway or
impaired drainage and elimination of soluble Aβ as it becomes
impeded by aggregatedAβ and possibly by immune complexes. In
addition, human Aβ immunotherapy trials, both active (8, 41) and
passive (64, 65), encountered side effects comprising focal abnor-
malities in the cerebral white matter on imaging, interpreted as
amyloid-related imaging abnormalities, a lymphocyte response in
the CSF and variable deterioration in neurological function (102).
The pathophysiology underlying these side effects is as yet
unclear; they may be due partly to the impaired drainage of ISF
associated with the increase severity of CAA but may also be due
to the effects of immune complexes in relation to the cerebral
vasculature.
In CAA, Aβ is seen initially in the basement membranes
(Figure 4) and then occupies the whole thickness of the walls of
arteries and capillaries, suggesting that insoluble Aβ is deposited
in the ISF drainage pathway (16, 18, 24, 40).
Active immunization of humans and mice with Aβ results in
decreased plaque load that correlates with the anti-Aβ titre in
serum, but the exact mechanism by which antibodies removeAβ is
not clear (10). It seems likely that anti-Aβ IgG enters the brain and
may form Aβ immune complexes, interfering with vascular func-
tion and impairing the perivascular drainage of Aβ. Immune com-
plexes formed in the brain parenchyma generate a robust and
long-lasting inflammatory response, characterized by increased
expression of the microglia markers CD11b, CD68 and FcRII/III,
but this feature is absent in the immunized Fcγ receptor-null mice
(104).
Immune complexes in the walls of arteries
disrupt perivascular drainage of ISF
and solutes
We tested the hypothesis that immune complexes disrupt the
perivascular drainage of solutes along the walls of arteries in
normal brains but not in brains of mice lacking Fcγ receptor. The
schedule for the experiments is summarized in Figure 7. Using the
presence of complement C3, IgG and ovalbumin as markers for
immune complex formation (101), we demonstrated that by 24 h,
immune complexes are localized to the basement membranes of
Figure 6. Proposed mechanism for CAA-induced dilatation of
perivascular spaces in the white matter. Branches of the leptomeningeal
arteries penetrate the cortex (often without branching) to supply the
subcortical white matter. CAA in the walls of the leptomeningeal arter-
ies (yellow banding) obstructs the drainage of interstitial fluid and
solutes resulting in retention of fluid in dilated perivascular spaces
around arteries in the white matter.
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the cerebral vasculature (17). This response is slower than the one
seen systemically, where immune complexes form within 10
minutes (70).
Normally, when solutes similar in molecular weight to Aβ are
injected in the grey matter, they diffuse through the extracellular
spaces of the brain and drain along the basement membranes of
capillaries and arteries within 5 minutes (15). In the animals in
which immune complexes had been allowed only 5 minutes to
form, there was no change in the pattern of distribution of soluble
dextran of 3 kDa at 5 minutes after its injection. At this time,
immune complexes were not detected in the cerebrovascular base-
ment membranes, permitting drainage of solutes in a physiological
manner.
At 24 h after the formation of immune complexes, confocal
microscopy revealed immune complexes in arterial basement
membranes (Figures 3 and 8). Quantitative assessment of
perivascular drainage in artery walls demonstrated that the
drainage of solutes from the brain was significantly impaired by
the presence of immune complexes in perivascular drainage
pathways (17).
Normally, by 24 h after its injection, dextran has been cleared
from the extracellular spaces and is present only in perivascular
macrophages around arteries in the ipsilateral hemisphere (15).
When left in situ for 24 h in mice with previously formed immune
complexes, dextran is taken up by macrophages in the ipsilateral
parenchyma, around veins, and by meningeal macrophages. This
suggests that, in the presence of inflammation induced by immune
complexes, solutes may become sequestered by inflammatory cells
and not cleared from the brain parenchyma.
At 7 days following the formation of immune complexes, the
pattern of drainage of soluble dextran was remarkably different. A
striking feature was the presence of dextran in the cellular infil-
trates around veins. This pattern of distribution suggests that the
dextran tracer is diverted from the extracellular space toward the
larger perivascular spaces around veins where it is taken up by
activated macrophages.We did not observe cuffs of dextran around
capillaries or arteries. There was a trend for the number of capil-
laries and arteries with dextran associated with their basement
membranes to decrease in the animals in which immune com-
plexes had been left for 7 days, but this did not reach statistical
significance. These results suggest that even in the presence of
inflammatory cells associated with the process of immune
complex formation and the taking up of dextran by macrophages,
perivascular drainage had returned to normal by 7 days.
In animals without the Fcγ receptor, perivascular drainage was
normal, with dextran tracer draining along the basement mem-
branes of capillaries and arteries, with very few veins involved.
This is consistent with the absence of inflammatory cells recruited
around veins in immunized Fcγ-deficient mice (104).
There are no reports of immune complexes forming in the brains
of humans immunized against Aβ. However, it is possible that Aβ
solubilized from plaques may encounter Aβ-specific antibodies,
generated in the process of immunotherapy, in the walls of cerebral
blood vessels.We know that there are high levels of complement in
transgenic mice that harbor Aβ mutations and that complement
colocalizes with the microvascular Aβ (35). Increased levels of C3
were also found to be associated with increased hemorrhages
following experimental immunotherapy (26, 52, 86, 109), suggest-
ing that immune complex formation may explain these side
effects. It has been reported that, following immunotherapy with
Aβ in mouse models, small amounts of anti-Aβ antibodies enter
the brain and form immune complexes that are cleared from the
Figure 7. Schematic diagram of the temporal sequence of immuniza-
tion and injection experiments. Wild-type BALB/c mice were immunized
with ovalbumin (OVA) and then injected with OVA in the striatum at
different time points. A soluble fixable fluorescent dextran was then
injected intracerebrally, 5 minutes or 24 h or 7 days post-immunization.
Reproduced from reference (17) Original Publisher: BioMed Central.
Figure 8. Immune complexes in basement
membranes in the walls of cerebral
capillaries and arteries. Active immunization
with ovalbumin (OVA) was followed by
intracerebral challenge with OVA and left in
situ for 24 h. The figure shows a longitudinal
section of an artery in the striatum at 24 h
after injection of antigen. There is
colocalization (yellow) of complement (green)
with laminin (red) in the basement
membranes surrounding smooth muscle
cells in the tunica media. Scale bar = 60 μm.
Reproduced from reference (17) Original
Publisher: BioMed Central.
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brain into the blood via the neonatal Fcγ receptors present
ubiquitously in the endothelia (28). The risk of intracerebral
hemorrhage may increase if immune complexes are formed in the
basement membranes of capillaries and arteries affected by CAA.
The vessel wall is already structurally weak from the deposition of
Aβ and is predisposed to aneurysm formation and rupture (19, 74,
75). Recently, it has been shown that active immunotherapy using
Aβ derivatives and alum in adult but not in aged Tg2576 mice
results in a reduction of Aβ burden, without worsening of CAA or
inducing microhemorrhages (4). If a number of blood vessels are
still unaffected by the morphological changes associated with
aging and deposition of Aβ, it may be sufficient to cope with the
drainage of theAβ solubilized from plaques, without rupturing the
vascular wall.
It remains unclear whether immune complexes are formed in the
extracellular spaces of the brain and then follow the perivascular
drainage route, or whether they form in situ within the arterial
basement membranes, or indeed whether immune complexes are
formed at all after immunization with Aβ. Our results suggest that
the absence of Fcγ receptors restores the ability of normal
perivascular clearance of solutes, supporting recent studies that
demonstrate that deletion of Fcγ receptors prevents the cognitive
impairment associated with AD (37).
Future prophylactic and therapeutic strategies in aging and CAA
will need to take into account the possibility that immune com-
plexes may interfere with perivascular drainage in patients treated
with Aβ immunotherapy.
PEFA IN CAA AND CADASIL
As discussed earlier, we have previously proposed reasons why
both CAA and CADASIL are categorized as PEFA disorders (16).
Although different types of PEFA involve failure of removal of
specific proteins, they share several risk factors, pathological pro-
cesses and a final common pathway, which also typify them as
angiopathies. CAAs are characterized by the vascular deposition
of different proteins such as Aβ, cystatin C and transthyretin
(91). In prion disease, insoluble prion protein accumulates mainly
in the brain parenchyma but the perivascular clearance of
anchorless prion protein induces PEFA-CAA (16). The most
common type of PEFA-CAA is associated with the deposition of
Aβ, which increases in old age and is observed in over 90% of
subjects with AD. All CAAs including the Aβ type, however,
foremost entail the parenchymal production or impaired metabo-
lism of specific protein(s), which aggregate to accumulate in pre-
dominantly cortical areas within the brain. Several processes
including uptake by macrophages or microglia are engaged in the
clearance of insoluble and degraded proteins from the cerebrum.
However, the perivascular lymphatic drainage pathways are an
important route for the bulk removal of degraded proteins and
solutes along with the ISF. With increasing age and likely greater
volumes of solutes and degraded proteins, this unique perivascular
system gradually loses its efficiency (49, 116). Walls of cerebral
arteries exhibiting arteriosclerosis also stiffen with age and lose
their elasticity over time. As a consequence of such weakening,
arteries fail to revert to their original form following the pulse
wave, leaving them dilated and with a stretched internal elastic
lamina (116). Age-related change within vascular basement mem-
branes, such as increased collagen in arteries that form the
perivascular pathways (14), is another factor that contributes to the
inflexibility of the vessel wall and favors deposition of insoluble
proteins and aggregates such as Aβ (7, 107).
CADASIL is characterized by widespread arteriolosclerosis,
multiple lacunar infarcts and microinfarcts within subcortical grey
and the deep white matter (123). There is an exclusive and wide-
spread distribution of the granular osmiophilic material (GOM) in
the walls of leptomeningeal arteries and cerebral arterioles. In
moderately advanced cases, an abundance of GOM is readily
detected as electron-densemasses sited at intervals around vascular
smooth muscle cells and along capillaries. The particulate rather
amorphous, 0.2–2 μm-sized Periodic acid-Schiff (PAS) positive
granular deposits accumulate in arteries (Figure 9) but may also be
found in capillary basementmembranes, frequently associatedwith
pericytes (34).Analogous to PEFA-CAA, the loss of arterial smooth
Figure 9. White matter changes and dilated PVS in non-amyloid
microangiopathies (eg, CADASIL) and CAA. Lobar or intracerebral
hemorrhages occur in CAA (unlike in CADASIL) whereas white matter
disease and microbleeds (cortical and subcortical) are common to both
disorders. Examination of the white matter reveals vascular degenera-
tive processes progressing from loss of smooth muscle cells, wall
thickening, fibrinoid necrosis to hyalinosis. Dilated PVS occur because
of arterial vascular degeneration and impaired perivascular drainage of
fluid and solutes in both CADASIL (A and C) and CAA (B and D). Dilated
PVS in the white matter is consistently observed to a greater extent in
CADASIL compared with CAA. Sections were stained with Hematoxylin
and Eosin (H&E) (A, B, D) and double immunofluorescence (C). In C, the
wall of an arteriole is labeled with smooth muscle α-actin (green) with
glial fibrillary acidic protein (GFAP)-labeled perivascular astrocytic pro-
cesses (red). Scale bars = 70 μm in A and B; 150 μm in C and D.
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muscle cells in CADASIL reduces vascular tone and amplitude of
pulsations for the propagation of perivascular lymphatic drainage
and results in further accumulation of other insoluble proteins along
with GOM. These deposits predominantly contain NOTCH3 frag-
ments but may accrue specific extracellular matrix proteins pro-
duced by vascular smooth muscle cells and capillaries (123). The
significance of the localization of GOM in the vasculature in terms
of the pathogenesis of CADASIL is still unclear. It is likely that
Extracellular Domain of the NOTCH3 Receptor (N3ECD)-
containing GOM is secreted by the vascular smooth muscle
and endothelial cells, possibly to remove potentially cytotoxic,
aggregation-prone mutant N3ECD, but its deposition and failure of
subsequent removal from the vessel walls incorporates CADASIL
within the spectrum of PEFA.
In CADASIL, vascular smooth muscle cells carrying copies of
the mutated NOTCH3 receptor appear affected by age-related
physiological changes and there is lack of normal replacement of
cells such that continued cell-to-cell signaling is impaired causing
ultimate breakdown in the integrity of the vascular wall. These
changes impact on function of vascular smoothmuscle cells leading
to abnormal arterial tone or contractibility (31, 61). The lack of
muscular tone in turn would reduce the motive force for perivascu-
lar drainage of solutes in the walls of long-perforating arteries
downstream to thewhitematter.Although such aberrations occur in
key targeted arterial segments defined by the cerebrovascular archi-
tecture (77) they presumably spread along the length of the vessel
and extend to other domains within themicrovascular network (81).
Focal vascular insufficiency in end arteries likely makes the poorly
perfused regions such as the white matter susceptible to infarcts.
The small deposits of GOM may also adhere to microvascular
walls, even inertly, but their accumulation in perivascular drainage
routes suggests that perivascular drainage of fluid and solutes is
impaired in CADASIL. One of the consequences of this could be
the characteristic enlargement of PVS (20). The dilated PVS result
from an even greater burden and insufficiency in the drainage of
ISF and degraded protein products into the lymphatic system
(116). However, such enlargement could also be attributed to the
loss of white matter in tandem with the increased tortuosity and
kinking of normally perforating vessels with focal loss of cellular
elements within artery walls.
White matter changes are particularly prominent in CADASIL.
This is because GOM is widespread even along white matter end
arteries and capillaries whereas in Aβ CAA, Aβ deposition is
largely restricted to cortical regions and the white matter changes
may result from effects of deposits within the cortex that affect
perfusion of the deep white matter as a consequence.
White matter damage and PEFA
Diffuse and focal white matter changes are a surrogate of small
vessel diseases of the brain and common to both CADASIL and
CAA (Figures 1 and 10). They manifest as cerebral WMH on
T2-weighted MRI or leukoaraiosis as a decreased signal on CT.
There is some controversy as to whether deep or periventricular
lesions are of more importance; this may depend on the definition
of boundaries between the periventricular and deep white matter
(67). The U-fibers within the white matter are frequently spared
but the pathological features comprise several patterns of
alterations including pallor or swelling of myelin, loss of
oligodendrocytes, axons and myelin fibers, foci of cavitation with
or without macrophages and areas of reactive astrogliosis (100).
However, white matter changes primarily reflected by increased
fluid mobility within the tissue may incorporate a range of patho-
logical entities including white matter rarefaction, incomplete
infarction, lacunar infarcts, microinfarcts, dilated PVS and loss of
myelin as well as axonal (or wallerian) degeneration. Several
imaging studies have demonstrated independent associations
between cerebral white matter changes and disability, comorbidity
and cognitive dysfunction in older age (29). Previous
neuroimaging studies indicated that dilated PVS increase with age
and their size in the white matter of the frontal lobe is related to
cognitive impairment (27, 84). Diffusion tensor imaging studies
(82) suggest that tissue microstructural changes in white matter
tracts and subcortical regions, for example putamen and thalamus,
are related to worsening clinical outcomes in sporadic small vessel
diseases and CADASIL. Extensive WMH in CADASIL also
appear to be associated with increased brain volume (124). The
progression of the microangiopathy with increasing age may also
promote the dilation of PVS throughout the whole brain but with
variable extent according to cerebral location. The severity of
dilated PVS in the temporal lobes and subinsular areas was,
however, found to be specifically related to the extent of WMH
(125). The signal changes relate not only to loss of white matter
tissue but also to increased fluidity and global increase in water
content of the cerebral tissue.
While some studies have yielded contradictory results on the
exact association betweenWMH and CAA (96), it is clear that the
frequency of WMH is increased in CAA compared with normally
aging subjects without evidence of CAA (3). However, in both
CAA and CADASIL, age-related arteriosclerotic changes coupled
with the characteristic deposition of insoluble proteins along long-
perforating arteries may affect perfusion of the deeper structures,
particularly the white matter (56). The lack of perfusion as attested
in moderate to severe CAA leads to a chronic hypoxic state in the
deep white matter with induction of essential control factors such
as the hypoxia-inducible factor 1α (38).
Figure 10. WMH in CADASIL. FLAIR MRI scan shows the extent of
confluent white matter changes in a 56-year-old CADASIL subject car-
rying the p.Arg182Cys mutation.
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White matter infarcts in CADASIL
Recent imaging studies in CADASIL examined the spatial rela-
tionship between the development of incident lacunes or small
infarcts andWMH in relation to the vascular anatomy to reveal the
mechanistic links between the two lesion types. Remarkably, the
majority (>90%) of lacunes develop at the edge of WMH rather
within or outside and they also develop proximal to a WMH along
the course of perforating vessels supplying the respective brain
region (32). These findings suggest that the mechanisms of lacunes
and WMH are intimately connected but they identify the edge of
WMH as a predilection site for lacunes. As discussed earlier, it is
possible that white matter changes in CAA may arise because of
several mechanisms; it is plausible that microinfarcts and border
zone infarcts associated with CAA (80) are progenitors of changes
in the deep white matter.
Impaired blood flow and cellular mechanisms
in CADASIL
In CADASIL, the widespread white matter axonal changes, par-
ticularly in the frontal lobe, may arise from differential stenosis
and sclerosis of arterioles (25), possibly affecting certain axon
bundles connecting to targets in the subcortical structures, specifi-
cally degeneration of thalamocortical pathways causing cortical
atrophy (62). Lesions within the white matter also include
spongiosis, that is vacuolation (122). Consistent with this finding,
increased volumes of PVS were related to white matter myelin
protein changes (122), indicating that reduction in white matter
volume is possibly one factor that causes dilated PVS.
The cellular mechanisms involved in loss of myelin and abnor-
malities in axons in CADASIL are yet to be determined. Lack of
integrity of artery walls and endothelia is likely to reduce both
blood flow and volume in affected frontotemporal white matter
(centrum semiovale) and subcortical grey matter structures and
affect the hemodynamic reserve by decreasing the vasodilatory
response. As supported by previous studies (20), this indicates that
blood flow and volume are reduced in demented CADASIL sub-
jects compared with those with no cognitive impairment.
Endothelial cell abnormalities and angiopathic changes may also
contribute to white matter damage and blood–brain barrier disrup-
tion can cause osmotic demyelination. Disruption of the blood–
brain barrier would also result in increased permeability of the
vessel wall and leakage of adverse factors, such as macrophages,
lymphocytes and complement (123). Neuronal apoptosis has been
described predominantly in neocortical layers III andV as a crucial
mechanism for cell death in CADASIL (110). It is unclear whether
this occurs secondary to the cerebral hypoperfusion, particularly in
the white matter, but it is likely to contribute to cortical atrophy
and to affect frontal lobe cognitive functions (20).
Another factor that could possibly impact the white matter
changes in both CADASIL and CAA is the occlusion of veins and
venules by collagenous thickening of the vessel walls. Venous
collagenosis increases with age and it has been demonstrated that
perivenous collagenosis increases in concert with leukoaraiosis
(11). The presence of apoptotic cells in white matter adjacent to
areas of leukoaraiosis suggests that such lesions are dynamic, with
progressive cell loss and expansion (11). In turn, vascular stenosis
caused by collagenosis may induce chronic ischemia or edema in
the deep white matter leading to capillary loss and more wide-
spread effects on the brain (12, 13).
CONCLUSIONS
In this review, we have examined the clinical and pathological
evidence for the failure of elimination of ISF and solutes from the
brain as a significant cause of pathology, particularly in the aging
brain. This failure is reflected in the PEFA that extends from the
common amyloid angiopathies to the less common CADASIL.
The failure of ISF drainage, particularly from the aging brain and
compounded by amyloid angiopathy, is a significant factor in the
pathogenesis of dementia. Development of therapeutic strategies
that facilitate the drainage of ISF and soluble metabolites from the
aging brain would be a fruitful path to follow for the prevention
and treatment of dementia.
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